Basic Information

Gene symbol S Synonyms E2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description spike glycoprotein

GTO ID GTC2671
Trial ID NCT04860297
Disease COVID-19
Altered gene S
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment mRNA-1273|Elasomeran|Spikevax
Location approved UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US
PhasePhase3
Recruitment statusCompleted
TitleA Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls
Year2021
CountryUnited States
Company sponsorModernaTX, Inc.
Other ID(s)mRNA-1273-P304
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: unvaccinated prior
Administration route intramuscular injection
Dosage mRNA-1273, 100µg, Day 1 and Day 29
Age Adult, Older_Adult
Cohort2: vaccinated
Administration route intramuscular injection
Dosage mRNA-1273, 100µg, , at least 4 months from the last dose; SOT recipients who completed primary COVID-19 vaccination series under EUA: RNA-1273, 100 µg, booster dose, on booster dose Day 1
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph